What Are Selank and Semax? Research Guide

Selank and Semax research guide

Selank and Semax are searched as individual peptide names, as paired comparison terms, and as components inside nasal-format catalog listings. Those search paths can mix several different record types: public chemistry pages, standalone vial product pages, nasal-format product pages, blend pages, and analytical PDFs. A useful review keeps those records separate.

This guide is written for qualified catalog review, product-page comparison, documentation checks, and internal linking only. It does not provide human-use instructions, veterinary-use instructions, preparation instructions, route guidance, study-design guidance, or outcome claims.

Selank and Semax identity at a glance

PubChem lists Selank under CID 11765600, with formula C₃₃H₅₇N₁₁O₉. PubChem lists ACTH (4-7), Pro-Gly-Pro with Semax as a synonym and formula C₃₇H₅₁N₉O₁₀S. These public identity pages are useful for name matching, formula checks, and synonym review.

Public identity pages are not product-specific lot documents. They do not prove that a Purity Collective vial, nasal-format listing, or blend matches a submitted sample. Product review still needs the exact product URL, listed quantity or size, SKU, format statement, and documents linked from that exact page.

Purity Collective product records in this cluster

Purity Collective currently separates this cluster across standalone vial records, single-component nasal-format records, and blend-format records:

Selank 10mg: a lyophilized vial listing with linked UPLC/MS and endotoxin documents.
Semax 10mg: a lyophilized vial listing with linked UPLC/MS and endotoxin documents.
Selank Nasal Spray 5mg and Semax Nasal Spray 5mg: nasal-format catalog records that currently disclose no product-specific analytical PDF.
Selank + Semax Nasal Spray: a two-component nasal-format listing with no linked product-level analytical report at this time.
Semax + Selank + Dihexa Nasal Spray: a three-component nasal-format listing that includes Semax, Selank, and Dihexa. PubChem lists Dihexa separately, but this guide cites that record only for identity context.

The important rule is simple: a documented vial page does not document a nasal-format page, and a blend page does not inherit standalone component evidence. Each record needs to be reviewed on its own product facts.

How to review the Selank 10mg vial documents

The Selank 10mg page links a Selank 10mg UPLC/MS report and a separate Selank endotoxin report. The product page states that lot PCCL-240644 records a 10.21mg measured quantity against a 10mg specification and a 99.37% purity result for the submitted sample. It also states that the endotoxin report records below 0.05 EU/mL and does not print an acceptance specification.

Those values should stay attached to the exact report and lot. They should not be reused as proof for Selank Nasal Spray 5mg, the Selank + Semax nasal-format listing, or any future product record unless a current document explicitly connects the exact listing and saleable lot.

How to review the Semax 10mg vial documents

The Semax 10mg page links a Semax 10mg UPLC/MS report and a separate Semax endotoxin report. The page states that lot PCCL-1902514-P records a 9.8mg measured quantity against a 10mg specification and a 99.18% purity result for the submitted sample.

The Semax page also states that the endotoxin document records below 0.05 EU/mL, does not print an acceptance specification, and displays an analysis date earlier than the received date. Those fields should remain visible during review. A document limitation is not a page defect when it is clearly disclosed; it is part of the record a buyer should evaluate.

How to review nasal-format and blend pages

The nasal-format product pages use “nasal spray” as a catalog format. That phrase should not be read as instructions. The nasal-spray format guide provides broader format context, while the COA review guide explains how to compare compound, lot, method, date, specification, and result fields.

For Selank Nasal Spray 5mg, Semax Nasal Spray 5mg, Selank + Semax Nasal Spray, and Semax + Selank + Dihexa Nasal Spray, the current public pages disclose that no product-specific analytical PDF is linked. That status should not be patched over with standalone vial reports. It should remain visible until product-level documents are attached and matched to the exact listing.

This structure also helps purchasing teams compare records without losing the source trail. A standalone vial page can be complete for its own product while a related format page remains document-pending. The guide’s job is to make that difference easy to see, not to turn separate catalog entries into one combined evidence package.

Selank and Semax product-record checklist

Choose the exact record: Selank vial, Semax vial, single-component nasal format, two-component blend, or three-component blend.
Match the product URL, title, SKU, listed quantity or size, format statement, and document status.
Keep Selank 10mg values tied to the Selank 10mg page and lot PCCL-240644.
Keep Semax 10mg values tied to the Semax 10mg page and lot PCCL-1902514-P or related endotoxin lot PCCL-1902514-E.
Do not transfer vial documents to nasal-format or blend listings.
Use PubChem records for identity context, not as Purity lot-level evidence.

Selank and Semax FAQs

What are Selank and Semax?

Selank and Semax are peptide names listed in public identity records. For Purity Collective review, they should be matched to the exact product page and document package being evaluated.

Which pages have linked analytical documents?

The Selank 10mg and Semax 10mg vial pages currently link product-specific UPLC/MS and endotoxin documents. The nasal-format pages currently disclose no linked product-specific analytical PDF.

Can Selank 10mg documents support Selank Nasal Spray 5mg?

No. The Selank 10mg documents belong to the vial product record unless a current product document explicitly connects another exact listing and saleable lot.

Can Semax 10mg documents support Semax Nasal Spray 5mg?

No. The Semax 10mg documents belong to the vial product record and should not be transferred to the nasal-format record.

How should the Selank + Semax nasal-format blend be reviewed?

Review it as its own catalog record with its own listed components, stated quantities, SKU, format, and documentation status. Do not use standalone component reports as blend proof.